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Abstract
Background: The presentation of pulmonary tuberculosis (PTB) in young children is often clinically
indistinguishable from other common respiratory illnesses, which are frequently infections of viral aetiology. As little
is known about the role of viruses in children with PTB, we investigated the prevalence of respiratory viruses in
children with suspected PTB at presentation and follow-up.
Methods: In an observational cohort study, children < 13 years were routinely investigated for suspected PTB in Cape
Town, South Africa between December 2015 and September 2017 and followed up for 24 weeks. Nasopharyngeal
aspirates (NPAs) were tested for respiratory viruses using multiplex PCR at enrolment, week 4 and 8.
Results: Seventy-three children were enrolled [median age 22.0 months; (interquartile range 10.0–48.0); 56.2% male
and 17.8% HIV-infected. Anti-tuberculosis treatment was initiated in 54.8%; of these 50.0% had bacteriologically
confirmed TB. At enrolment, ≥1 virus were detected in 95.9% (70/73) children; most commonly human rhinovirus
(HRV) (74.0%). HRV was more frequently detected in TB cases (85%) compared to ill controls (60.6%) (p = 0.02). Multiple
viruses were detected in 71.2% of all children; 80% of TB cases and 60.6% of ill controls (p = 0.07). At follow-up, ≥1
respiratory virus was detected in 92.2% (47/51) at week 4, and 94.2% (49/52) at week 8.
Conclusions: We found a high prevalence of viral respiratory co-infections in children investigated for PTB, irrespective
of final PTB diagnosis, which remained high during follow up. Future work should include investigating the whole
respiratory ecosystem in combination with pathogen- specific immune responses.
Keywords: Respiratory viruses, pulmonary tuberculosis, Paediatric
Background
An estimated 1 million children < 15 years develop tuber-
culosis (TB) every year [1]. Pulmonary TB (PTB) contrib-
utes to approximately 75% of the TB disease burden in
children, and is difficult to confirm given the paucibacil-
lary nature of the disease and challenges in obtaining good
quality respiratory samples in young children [2]. More-
over, the clinical diagnosis of PTB in children is frequently
complicated by non-specific clinical presentations, which
overlap with other common respiratory illnesses [3]. This
is especially true in young children living in developing
countries, particularly in settings where human immuno-
deficiency virus (HIV) is endemic [4].
There are limited data available on the prevalence of
respiratory virus co-infection in children with suspected
PTB [5], while children under 5 years of age carry the
highest burden of not only TB, but also of other acute
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non-TB respiratory tract infections [6, 7]. After careful
clinical investigation and follow up, many children that
present with symptoms suggestive of PTB are found to
have diagnoses other than TB. This group needs to be
better characterised to help clinical decision making and
reduce unnecessary treatment. Respiratory virus infec-
tions likely play a crucial role in the aetiology of disease
in this group of children [8]. In addition, viruses could
play a role in the inception, presentation, and disease
progression of children with PTB, by disrupting the im-
munological response of the host. Alternatively, TB dis-
ease might facilitate viral co-infection which could in
turn lead to an altered TB disease presentation or more
severe TB disease [9]. There is a clear need to improve
our current understanding of the role of respiratory co-
infections in the interaction between the developing im-
mune system and Mycobacterium tuberculosis (M.tb).
In order to advance our understanding of the inter-
action between respiratory viruses and PTB in children,
we performed a preliminary study to explore the preva-
lence of viral respiratory co-infections in children with
TB symptoms (including children ultimately diagnosed
with and without PTB) at presentation and during
follow-up.
Methods
Cohort recruitment and procedures
This analysis was part of a larger hospital-based observa-
tional cohort. Study methods have been previously de-
scribed [10]. In brief, symptomatic children < 13 years of
age, routinely presenting to two public hospitals with a
history and well-characterized symptoms of suspected
PTB [10, 11], were consecutively enrolled from Decem-
ber 2015 until September 2017. We also considered that
TB may present acutely, especially in young children,
and included children with any duration of cough, if ≥1
of the following were present: 1) exposure to an identi-
fied TB source case in the past 12 months, 2) positive tu-
berculin skin test (TST) if previously negative or
unknown, or 3) a chest radiograph (CXR) suggestive of
TB as assessed by the study clinician. We collected at
least 3 respiratory specimens for smear microscopy,
Xpert® MTB/RIF, and liquid culture at enrolment. Speci-
mens were processed at the National Health Laboratory
Service, (NHLS) Tygerberg Hospital following standard
protocols. Other investigations included HIV testing,
TST (Mantoux, 2 Tuberculin Units PPD RT-23, Statens
Serum Institute, Copenhagen) and a digital CXR
(antero-posterior and lateral), evaluated by two inde-
pendent experts or a third reader in order to reach con-
sensus [12]. Follow-up visits were done 4, 8 and 24
weeks after enrolment or start of TB treatment and in-
cluded sampling for respiratory viruses.
Virus detection
Nasopharyngeal aspirates (NPAs) were collected in a
sterile container by nasopharyngeal suctioning with a
mucus extractor (Lasec, South Africa) at enrolment, 4
and 8 weeks later. Samples were transported in a cooler
box to the reference NHLS Medical Virology Laboratory
within 4 h. Commercially available virus transport
medium (Davies Diagnostics, Grenada Spain) was added
in the laboratory. Total nucleic acid extraction was done
with the NUCLISENS® easyMAG® (bioMérieux, Marcy
l’Etoile, France). Viruses were identified using a com-
mercially available multiplex PCR (Anyplex™ II, RV16,
Seegene) which includes 16 viruses considered clinically
and epidemiologically relevant. These were Adenovirus
(AdV), Influenza A/B virus (InfV A/B), Parainfluenza-
virus 1–4 (PIV 1–4), human Rhinovirus A/B/C (HRV A/
B/C), Respiratory syncytial virus A and B (RSV A/B), hu-
man Bocavirus 1–4 (HBoV 1–4), human Metapneumo-
virus (hMPV), human Coronavirus 229E, NL63, OC43
(HCoV 229E/NL63/OC43), and human Enterovirus
(HEV). The standard PCR cycle thresholds were used ac-
cording the manufacturers recommendations.
At baseline, samples were analysed in real-time, while
follow up samples were analysed after storage at − 80 °C
for 2–3 years.
Classification of TB cases
Attending ward clinicians (and not the study team) were
responsible for TB treatment decisions, according to na-
tional TB guidelines, and all TB test results were avail-
able to them. Children were followed for 24 weeks (6
months) or until TB treatment completion. All children
were retrospectively classified according to international
consensus clinical case definitions for paediatric PTB [8];
“confirmed TB”, “unconfirmed TB” and “unlikely TB”.
Final categories were assigned after follow-up, allowing
for assessment of treatment response and review of cul-
ture results. Children classified as “unlikely TB” are re-
ferred to as “ill controls” for analysis purposes. Ill
controls were initially investigated for suspected PTB,
however an alternative diagnosis was made and symp-
toms improved without TB treatment.
Statistical analysis
Analyses were performed using SPSS Inc. (2001 Chicago
USA version 26). Pearson’s Chi- squared test was used
to compare the prevalence of viral pathogens between
TB cases (confirmed and unconfirmed) and ill controls
at enrolment. The Yates continuity correction was used
if the expected cell size was less than 5.
Results
Seventy-three children were enrolled, median age 22
months (interquartile range (IQR) 10.0–48.0); 56.2%
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were male and 17.8% were HIV-infected (Table 1). TB
treatment was started in 54.8%; of which 50.0% were
confirmed. Children with confirmed TB had more fre-
quent documented exposure to TB, a positive TST result
and a CXR suggestive of PTB compared to unconfirmed
TB cases and ill controls. The clinical presentation was
similar for all three groups (confirmed TB, unconfirmed
TB, and ill controls).
All 73 children had NPAs collected at enrolment,
69.9% (51/73) at week 4 and 71.2% (52/73) at week 8.
Forty-three (58.9%) children had samples collected at all
three time points. See Fig. 1 for flowchart of the study
participants and study outcomes. There were no deaths
reported; 67/ 73 (91.8%) children completed 6 months
study follow-up. Thirty-six of 40 TB cases (90.0%) com-
pleted TB treatment and 4 of the TB cases withdrew be-
fore the end of the study.
At baseline, one or more viruses were detected in
95.9% (70/73) of children (Table 2). HRV was the most
common, detected in 74.0% (54/73) of children, in 85%
(34/40) of TB cases and in 60.6% (20/33) of ill controls,
(p = 0.02). AdV was the second most detected virus,
identified in 54.8% (40/73) of children, in 60% (24/40) of
TB cases, and in 48.5% (16/33) of ill controls (p = 0.33).
A single virus was detected at enrolment in 24.7% (18/
73) of children; in 15% (6/40) of TB cases and in 36.4%
(12/33) of ill controls (p = 0.04). Multiple viruses were
detected in 71.2% (52/73) of children; 80% (32/40) in TB
cases and 60.6% (20/33) of ill controls (p = 0.07).
Figure 2 shows the distribution of viruses detected in
all samples at baseline and follow-up visits through a
calendar year. Most viruses were detected throughout
the year with some minor seasonal variation, while influ-
enza virus was only detected from June to November,
and RSV was detected from February to August, peaking
in May.
Table 3 presents data on viruses detected at follow-up,
4 and 8 weeks after enrolment. Overall, the prevalence of
viruses detected remained similar at follow up compared
to baseline. One or more viruses were detected in 95.9%
(70/73) children at enrolment, with 92.2% (47/51) chil-
dren positive at week 4 and 94.2% (47/51) at week 8.
HRV, HEV and AdV were the most detected viruses
during follow up for both TB cases and ill controls.
Respiratory symptoms had resolved in 34 of 52
(65.4%) children when sampled at week 8. All these
asymptomatic children still had one or more viruses de-
tected at week 8, with HRV detected in 91.2% (31/34)
Table 1 General characteristics of children investigated for pulmonary TB (n = 73)
Demographics All (n = 73; 100) Ill controls (n = 33; 45.2) Confirmed TB (n = 20; 27.4) Unconfirmed TB (n = 20; 27.4) P-value
Male 41 (56.2) 21 (63.6) 10 (50.0) 10 (50.0) 0.57
Age (months) 22.0 (10.0–48.0) 22.0 (7.5–48.0) 18.0 (8.3–58.0) 22.5 (15.8–40.0) 0.66
Mixed Race 48 (65.8) 21 (63.6) 15 (75.0) 12 (60.0) 0.66
HIV exposeda 16 (21.9) 6 (18.2) 6 (30.0) 4 (20.0) 0.59
HIV infected 13 (17.8) 6 (18.2) 3 (15.0) 4 (20.0) 1.0
Household size 5.0 (4.0–7.0) 5.0 (4.0–7.5) 6.0 (4.0–7.8) 5.0 (3.3–7.0) 0.84
Documented TB exposure 35 (47.9) 11 (33.3) 15 (75.0) 9 (45.0) 0.01
Previous TB treatment 9 (12.3) 5 (15.2) 2 (10.0) 2 (10.0) 0.82
Positive TSTb 23 (31.5) 4 (12.1) 12 (60.0) 7 (35.0) < 0.01
Presenting signs and symptoms
Cough
Duration (days)
68 (93.2)
14 (7–42)
31 (93.9)
14 (7–42)
18 (90.0)
14 (7–26)
19 (95.0)
14 (7–60)
0.86
0.78
Wheeze
Duration (days)
31 (42.5)
1 (1–2)
13 (39.4)
1 (1–2)
10 (50.0)
1 (1–2)
8 (40.0)
2.5 (1–3)
0.76
0.22
Fever
Duration (days)
39 (53.4)
4 (3–21)
18 (54.5)
4 (3–11)
12 (60.0)
4 (2–28)
9 (45.0)
7 (3–53)
0.63
0.73
Lack of appetite 39 (53.4) 15 (45.5) 12 (60.0) 12 (60.0) 0.48
Lethargy 26 (35.6) 11 (33.3) 9 (45.0) 6 (30.0) 0.67
Poor growthc 37 (50.7) 15 (45.5) 10 (50.0) 12 (60.0) 0.36
Recent antibiotics 36 (49.3) 15 (45.5) 9 (45.0) 12 (60.0) 0.66
CXR suggestive of TBd 31 (42.5) 7 (21.2) 16 (80.0) 8 (40.0) < 0.01
TST Tuberculin skin test, CXR Chest x-ray
Numbers are presented with percentages in brackets. Median values are presented with interquartile range (IQR). P values are calculated using Chi square test for
dichotomous variables and Kruskal-Wallis for continuous variables
an = 72 due to missing data. bn = 63 due to missing data. cn = 65 due to missing data. dn = 72 due to poor quality of the CXR
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Fig. 1 Flowchart of study participants, viral sampling and study outcomes. Flowchart of study participants from baseline to end of the study
(week 24)
Table 2 Detection of viruses in all children with suspected TB at baseline, in TB cases (confirmed and unconfirmed) and in ill
controls (n = 73)
All (n = 73; 100) TB cases (n = 40, 54,8) Ill controls (n = 33; 45.2) P Value
No virus detected 3/73 (4.1) 2/40 (5.0) 1/33 (3.0) 1.00
Single virus 18/73 (24.7) 6/40 (15.0) 12/33 (36.4) 0.04
≥ 1 virus 70/73 (95.9) 38/40 (95.0) 32/33 (97.0) 1.00
≥ 2 viruses 52/73 (71.2) 32/40 (80.0) 20/33 (60.6) 0.07
≥ 3 viruses 41/73 (56.2) 27/40 (67.5) 14/33 (42.4) 0.03
Human Rhinovirus 54/73 (74.0) 34/40 (85.0) 20/33 (60.6) 0.02
Enterovirus 41/73 (56.2) 25/40 (62.5) 16/33 (48.5) 0.23
Respiratory syncytial virus (A/B) 9/73 (12.3) 5/40 (12.5) 4/33 (12.1) 1.00
Adenovirus 40/73 (54.8) 24/40 (60.0) 16/33 (48.5) 0.33
Coronavirus (229E, OC43, NL63) 9/73 (12.3) 7/40 (17.5) 2/33 (6.1) 0.17
Bocavirus 20/73 (27.4) 14/40 (35.0) 6/33 (18.2) 0.11
Influenza (A/B) 4/73 (5.5) 3/40 (7.5) 1/33 (3.0) 0.62
Parainfluenza virus (1–4) 17/73 (23.3) 11/40 (27.5) 6/33 (18.2) 0.35
Human metapneumovirus 1/73 (1.4) 1/40 (2.5) 0 1.00
Chi-square was used to detect differences between TB cases (confirmed and unconfirmed) and ill controls. The Yates continuity correction was used if the
expected cell size was less than 5
Respiratory syncytial virus (RSV) A was detected in 3 samples and RSV B in 7 samples. One child had simultaneous detection of RSV A and B. Influenza A and B
were simultaneously detected in 2 different samples (from different children or the same child). Parainfluenza virus (PIV) 1 and 2 were detected in 5 samples (two
samples had simultaneous detection of PIV1&2), PIV 3 was not detected at all and PIV 4 was detected in 9 samples
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Fig. 2 Seasonal distribution of viruses detected in children with suspected pulmonary TB. Human Rhinovirus (HRV, includes A/B/C), Adenovirus
(AdV), Respiratory syncytial virus (RSV, includes A/B), Influenza virus (InfV, includes A/B), human Bocavirus (HBoV, includes 1–4), human Enterovirus
(HEV), human Metapneumovirus (hMPV), Parainfluenza virus (PIV, includes 1–4) and human Coronavirus (HCoV, includes 229E/NL63/OC43). The
seasonal distribution of the respiratory viruses detected in samples combined from enrolment and follow-up (TB cases and ill controls). The black
line represents the number of samples collected during that month. The samples were collected from December 2015 until September 2017,
therefore more samples were collected in the months January through September
Table 3 Detection of viruses during follow up at weeks 4 (n = 51) and 8 (n = 52) in children with suspected pulmonary TB
All children TB Cases Ill controls
Week 4
n = 51
Week 8
n = 52
Week 4
n = 26
Week 8
n = 27
Week 4
n = 25
Week 8
n = 25
No virus detected 4 (7.8) 3 (5.8) 1 (3.8) 2 (7.4) 2 (8.0) 1 (4.0)
Single virus 7 (13.7) 9 (17.3) 2 (7.7) 4 (14.8) 5 (20.0) 5 (20.0)
≥ 1 virus 47 (92.2) 49 (94.2) 25 (96.2) 25 (92.6) 23 (92.0) 24 (96.0)
≥ 2 viruses 41 (80.4) 40 (76.9) 23 (88.5) 21 (77.8) 18 (72.0) 19 (76.0)
≥ 3 viruses 30 (58.8) 32 (61.5) 16 (61.5) 18 (66.7) 14 (56.0) 14 (56.0)
Human Rhinovirus 43 (84.3) 43 (82.7) 22 (84.6) 20 (74.1) 21 (84.0) 23 (92.0)
Enterovirus 26 (51.0) 29 (55.8) 14 (53.8) 17 (63.0) 12 (48.0) 12 (48.0)
Respiratory syncytial virus (A/B) 6 (11.8) 3 (5.8) 4 (15.4) 4 (14.8) 2 (8.0) 1 (4.0)
Adenovirus 33 (64.7) 31 (59.6) 17 (65.4) 15 (55.6) 16 (64.0) 16 (64.0)
Coronavirus (229E, OC43, NL63) 4 (7.8) 9 (17.3) 3 (11.5) 8 (29.6) 1 (4.0) 1 (4.0)
Bocavirus 13 (24.5) 16 (30.8) 7 (26.9) 9 (33.3) 6 (24.0) 7 (28.0)
Influenza (A/B) 1 (2.0) 4 (7.7) 1 (3.8) 4 (14.8) 0 (0) 0 (0)
Parainfluenza virus (1–4) 15 (29.4) 15 (28.8) 8 (30.8) 9 (33.3) 7 (28.0) 6 (24.0)
Human metapneumovirus 0 1 (1.9) 0 (0) 1 (3.7) 0 (0) 0 (0)
Numbers are presented with percentages in parentheses
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and AdV in 61.8% (22/34). Multiple viruses were de-
tected in 20.6% (7/34) of asymptomatic children (Sup-
plementary Table 1).
Discussion
To our knowledge this is the first study investigating the
prevalence of respiratory viruses in children presenting
with suspected PTB and documenting the presence of
viruses at presentation and during follow-up. We found
a very high prevalence of respiratory viruses in all chil-
dren, with HRV and AdV being the most frequently de-
tected. The burden of respiratory viruses remained high
at follow up, showing persistent high viral carriage.
There was no clear association between viruses and TB
disease categories, but HRV and multiple virus detec-
tions were more frequently seen in TB cases compared
to ill controls.
Although there is limited paediatric data on what con-
stitutes a protective immune response after M.tb expos-
ure, a predominant T helper 1 response is considered
protective, while a T helper 2 response is associated with
severe and disseminated TB disease [13, 14]. We specu-
late that concurrent or sequential infections of M.tb and
respiratory viruses may lead to an altered host immune
response, which may result in inadequate containment
of M.tb infection [15]. In support of this hypothesis, one
well-studied example is influenza virus infection which
often is associated with subsequent bacterial pneumonia
[16]. This increased susceptibility to secondary bacterial
infections and decreased bacterial clearance has been at-
tributed to the deleterious effects of viruses on innate
immunity [16–19]. Evidence from mouse models sug-
gests that respiratory viruses such as influenza also im-
pair the development of acquired immunity against
M.tb, resulting in decreased protection and ability to
control disease [20, 21]. Likewise, M.tb infection may re-
sult in a decreased immune response against subsequent
viral infections. Viral infections may lead to exacerbation
of TB disease and/or reactivation of TB infection [20,
21]. Although there are no data available on viral clear-
ance in children with PTB, several studies have shown
prolonged detection of viruses in individuals living with
HIV or with lung conditions such as asthma or cystic fi-
brosis, compared to healthy controls [22–24]. In order
to unravel the complex relationship between M.tb and
respiratory viruses, future work should include investiga-
tion of organism-specific immune responses.
The literature on respiratory co-infections in children
with TB is limited. The only comparable study of chil-
dren with suspected PTB in South Africa was by Dube
and colleagues [5]. Overall, the authors detected viruses
less frequently than in our study. HMPV was the most
prevalent virus detected in that study, in 19% of all the
children, compared to < 2% HMPV prevalence in our
study population, whereas HRV was detected in 15% of
children, compared to 74% in our study. Both studies
were conducted over the course of a complete calendar
year, making seasonal variation an unlikely explanation
for the differences observed, however differences be-
tween years when the respective studies were done could
partly explain this. Some notable differences between
these studies include the age of the study population, the
geographical location they were recruited from and the
sampling method. Children in our study were younger
(22 vs 36 months) and we collected NPAs and not naso-
pharyngeal swabs. Viral detection is generally higher in
younger children due to immature immunity (leading to
increased viral replication), first exposure to particular
virus strains, therefore lacking adaptive immune re-
sponses and higher viral exposure at day care and
crèches [25, 26]. The different sampling strategies could
also explain the differences between type and burden of
respiratory pathogens detected, with NPA possibly being
a more appropriate sample for viral detection in children
presenting with respiratory illnesses [27, 28]. Although
the respiratory virus detection rate is very high in our
cohort, the data are consistent with that reported in
young children with respiratory illnesses globally [29–
31]. In addition, the seasonal pattern seen in our study is
comparable to the South African surveillance data from
2016 to 2017, reported by the National Institute for
Communicable Diseases (NICD) [32]. In 2016 the NICD
reported that the RSV season started in February and
peaked in May, while influenza was detected from May
to November [32]. A temporal relationship between in-
fluenza virus and TB has been described, with influenza
activity being followed by a peak of PTB cases a few
months later; however, the number of influenza virus
positive samples in our study was too small to determine
an association [33].
In the literature polymicrobial detections are re-
ported in up to 30% of infants with a lower respira-
tory tract infection, and this has been linked to more
severe clinical disease, although the mechanism be-
hind this is not completely understood [34, 35]. In
our study, we found that TB cases more often had
multiple viral co-infections compared to ill controls.
This could be as a result of impaired immunity to re-
spiratory viruses due to M.tb infection or, conversely,
the multiple viruses result in impaired immunity and
an inadequate response to control TB infection. Both
scenarios are plausible and will likely depend on tim-
ing of pathogen exposure (both viral and M.tb) and
the maturity of the host immune system. However,
multiple viruses were also detected in > 20% of the
children without respiratory symptoms at follow-up,
indicating that further data on the clinical relevance
of viral detection in children are needed.
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HRV has been the most frequently detected respira-
tory pathogen since the introduction of molecular detec-
tion techniques [36], with prevalence reaching 50%
among children presenting with respiratory illnesses
[37]. The clinical relevance of HRV has often been de-
bated; historically, HRV was seen as a common cold
virus [38], however recently more severe lower respira-
tory infections due to HRV have been described [39, 40].
We found that HRV was more often detected in TB
cases (confirmed and unconfirmed) compared to ill con-
trols. Perhaps HRV infection facilitated a progression
from M.tb infection to disease, which is consistent with
some in vitro studies showing that HRV infection im-
paired phagocytosis and cytokine production against
bacteria in adults with chronic obstructive pulmonary
disease [41]. Alternatively, HRV co-infection could have
caused symptoms resulting in hospitalization and (early)
unmasking/detection of TB disease. This is consistent
with other studies showing more severe clinical presen-
tation of HRV infection in children who are younger
[42, 43], with lower premorbid lung function [44] or
other respiratory comorbidities [22, 23, 45].
AdV was the second most prevalent pathogen in our
study, detected in more than half of children, with no
differences between TB diagnostic categories. This
prevalence is higher than the AdV prevalence reported
in other studies [5, 29–31]. Dube and colleagues found
that 7% of children with suspected PTB had AdV [5].
The majority of primary AdV infections occur during
the first 5 years of life, and the age difference between
the two study populations could explain some of the dif-
ferences in AdV detection [46]. The high burden we ob-
served is concerning, as there is a known association
between AdV pneumonia and chronic pulmonary seque-
lae in young children. A meta-analysis showed that more
than half of children hospitalised with AdV pneumonia
had subsequent respiratory sequelae, including bronchi-
ectasis and bronchiolitis obliterans [47]. Although AdV
is often associated with severe respiratory disease, a pro-
spective study by Self and colleagues [48] showed that
AdV is also frequently detected in asymptomatic chil-
dren. Long-term follow up of these children and AdV
typing may elucidate the role of AdV infection on clin-
ical presentation and long-term sequelae in children
with and without PTB.
The comparable frequency of respiratory virus detection
in children from baseline and follow up samples is striking
and to our knowledge has not previously been described.
This is especially relevant because over 90% of children
that were asymptomatic at follow-up still had one or more
viruses detected. This could be due to an overall high bur-
den of respiratory viruses in our population, both in the
hospital setting (at enrolment) and in households/ com-
munity (during follow-up). Alternatively, respiratory viral
infections are often asymptomatic and may contribute to
a natural, or, in some, a disturbed, respiratory ecosystem.
This high viral detection seen in our study supports the
concept described by Man et al. [49], suggesting that the
clinical respiratory disease phenotype is a result of an
interplay between the entire respiratory microbiota and
host characteristics. They were able to differentiate chil-
dren with respiratory disease from healthy controls by
combining viral, bacterial, and host-related predictors. It is
therefore important to consider the entire respiratory eco-
system when investigating respiratory disease, rather than
focussing on single pathogen aetiology.
The main limitations of this study are the small sam-
ple size and the lack of healthy controls. Given that the
overall prevalence of viral infection was so high it was
not possible to directly assess the impact of viral co-
infection on severity of TB disease or presentation. The
small numbers limit our ability to show significant dif-
ferences between virus detection in TB cases and ill con-
trols, especially regarding their role in the clinical
presentation and severity of TB disease. In addition, we
lack samples prior to the current presentation; it is pos-
sible that viruses were present before children presented
with symptoms of TB. A strength of this study is the
careful follow-up of both TB cases and ill controls and
the repeated respiratory sampling to document longitu-
dinal prevalence of respiratory viruses in young children
with and without TB.
Conclusions
In summary, respiratory viral co-infections are fre-
quently seen in young children with suspected PTB and
viruses probably play an important role in the acquisi-
tion, control and presentation of PTB disease in young
children. The interaction between host immune re-
sponses, viral infections and TB is likely complex but
important to unravel to improve our understanding on
M.tb control and possible therapeutic interventions.
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